The stock has been fairly stable over the past year.

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two ...

(Reuters) - Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is ...